EDNRB产品信息
英文名称：Endothelin receptor type B
中文名称：内皮素B受体
靶点别称：EDNRB
物种：Human
属性：Protein
标记：Unconjugated/GFP Fusion
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
制剂（Formulation）
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
运输（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 12 months under sterile conditions.
EDNRB分子背景
Endothelin Receptor B (EDNRB) is a type of G protein-coupled Receptor with the N-terminus located outside the cell. It's widespread in the human body. EDNRB binds to ET and transmits information into the cell through the intracellular Ca2+ phospholipid-dependent protein kinase second messenger system, which promotes the rapid release of calcium in the endoplasmic reticulum and sarcoplasmic reticulum, resulting in the rapid increase of intracellular calcium concentration. Endothelin exerts its biological effects through its receptor (ETR). Endothelin and ETR constitute the endothelin axis. Endothelin axis has pro-tumor effects in various tumors including malignant melanoma (MM), including promoting tumor growth, anti-apoptosis, promoting angiogenesis and promoting tumor metastasis.
关键字： EDNRB;EDNRB蛋白;EDNRB重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。